California fails to stop 23andMe founder from re-acquiring company

A U.S. bankruptcy judge has cleared the $305 million sale of genetic testing company 23andMe to co-founder Anne Wojcicki's TTAM Research, rejecting California's bid to delay the transaction over genetic data privacy concerns. The judge ruled California's appeal was "likely to fail" and that customers would not be "irreparably harmed," citing their ability to delete data. This decision allows the sale to proceed despite objections from multiple states, following 23andMe's bankruptcy filing due to a demand drop and a 2023 data breach, underscoring the legal challenges surrounding sensitive data transfer in corporate restructurings.

Analysis

A U.S. bankruptcy court has cleared the path for 23andMe's sale to co-founder Anne Wojcicki's non-profit, TTAM Research, for $305 million, marking a critical step in the company's restructuring. The decision to reject California's bid to delay the sale is significant, as the judge ruled the state's appeal over its Genetic Information Privacy Act was "likely to fail" and that customers were not "irreparably harmed" due to their ability to delete data. This ruling effectively prioritizes the federal bankruptcy process over state-level privacy regulations, a key development for a company that filed for Chapter 11 in March following declining demand and a major 2023 data breach. The sale involves the transfer of approximately 10 million genetic profiles, including 1.8 million from California, which the state's attorney characterized as a "sale of DNA to a third party." The winning bid from TTAM Research, which surpassed a $265 million offer from Regeneron Pharmaceuticals, indicates perceived value in the company's assets despite its challenges, though the ongoing opposition from multiple states underscores the persistent legal and reputational risks tied to consumer genetic data.

Key Decisions for Investors

• The court's decision to overrule state privacy objections in a bankruptcy proceeding sets a noteworthy precedent; investors in data-intensive sectors should monitor for potential legislative responses that could redefine the value and risk associated with consumer data assets.
• While the sale provides a resolution for 23andMe's assets, the successor entity, TTAM Research, inherits significant reputational and legal risk stemming from unresolved privacy concerns and opposition from multiple states, which could impact its operational future.
• Regeneron's (REGN) unsuccessful $265 million bid confirms its strategic interest in acquiring large-scale genetic databases, an important insight for investors evaluating the company's long-term R&D and M&A strategy.